Heart Failure Systolic
📧 Sign up to get email alerts when something new happens for Heart Failure Systolic.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-11EMA Authorised: Edistride (dapagliflozin propanediol monohydrate) — AstraZeneca AB
Edistride, containing dapagliflozin propanediol monohydrate, has been authorised for treatment in type 2 diabetes, systolic heart failure, h…
-
EMA approval · 2026-06-11EMA Authorised: Forxiga (dapagliflozin propanediol monohydrate) — AstraZeneca AB
Forxiga (dapagliflozin propanediol monohydrate) has been authorised for use in the European Medicines Agency, with indications including Typ…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Cardiac Performance During Steep Trendelenburg Position in Patients Undergoing Robotic Surgery Surgery.
This clinical trial update indicates the study is currently recruiting to evaluate cardiac performance during steep Trendelenburg positionin…
-
CLINICAL_TRIALS trial_result · 2022-11-16Clinical Trial Update: Nicotinamide Riboside in Systolic Heart Failure [Phase 1, Phase 2]
Phase 1/2 trial investigating nicotinamide riboside for systolic heart failure; study completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2020-08-05Clinical Trial Update: Blended Collaborative Care for Heart Failure and Co-Morbid Depression [Phase 2, Phase 3]
Phase 2/3 clinical trial on blended collaborative care for heart failure with comorbid depression has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-04-30Clinical Trial Update: MADIT ASIA Cardiac Resynchronization Trial [Phase 3]
The Phase 3 MADIT ASIA Cardiac Resynchronization Trial sponsored by Boston Scientific was terminated; it enrolled patients with congestive h…